Verastem, Inc. (VSTM) Analysts See $-0.40 EPS

October 13, 2018 - By Dolores Ford

Investors sentiment increased to 2.07 in 2018 Q2. Its up 0.91, from 1.16 in 2018Q1. It is positive, as 15 investors sold Verastem, Inc. shares while 15 reduced holdings. 36 funds opened positions while 26 raised stakes. 30.86 million shares or 129.37% more from 13.46 million shares in 2018Q1 were reported.
Ameritas Prtn holds 3,771 shares or 0% of its portfolio. Creative Planning holds 0% in Verastem, Inc. (NASDAQ:VSTM) or 58,550 shares. Clarivest Asset Limited Liability Corp, California-based fund reported 64,900 shares. 129,005 were accumulated by Wells Fargo & Mn. Qs Ltd Llc has 0% invested in Verastem, Inc. (NASDAQ:VSTM). Moreover, Alliancebernstein L P has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 87,600 shares. Piedmont Advsr Ltd Llc holds 918 shares or 0% of its portfolio. Bridgeway Cap Inc holds 0.01% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 175,600 shares. United Automobile Association holds 0% or 11,945 shares in its portfolio. State Board Of Administration Of Florida Retirement System owns 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 14,470 shares. North Carolina-based Savings Bank Of America Corporation De has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Blackrock invested 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Aqr Capital Mngmt Ltd owns 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 67,422 shares. Deutsche Financial Bank Ag has 84,128 shares. Barrett Asset Ltd Llc holds 0.02% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 50,000 shares.

Analysts expect Verastem, Inc. (NASDAQ:VSTM) to report $-0.40 EPS on November, 6.They anticipate $0.21 EPS change or 34.43 % from last quarter’s $-0.61 EPS. After having $-0.30 EPS previously, Verastem, Inc.’s analysts see 33.33 % EPS growth. The stock decreased 9.31% or $0.58 during the last trading session, reaching $5.65. About 9.88M shares traded or 233.94% up from the average. Verastem, Inc. (NASDAQ:VSTM) has risen 69.08% since October 14, 2017 and is uptrending. It has outperformed by 53.46% the S&P500.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 3 analysts covering Verastem (NASDAQ:VSTM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Verastem had 4 analyst reports since May 2, 2018 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Thursday, May 10 report. FBR Capital maintained the stock with “Buy” rating in Friday, June 8 report.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $415.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More notable recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Fool.com which released: “Here’s Why Verastem Dropped Precipitously Today” on October 12, 2018, also Benzinga.com with their article: “41 Stocks Moving In Friday’s Mid-Day Session” published on October 12, 2018, Streetinsider.com published: “Verastem (VSTM) Announces NCCN Adds its COPIKTRA Capsules to Clinical Practice Guidelines in Oncology” on October 08, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) were released by: Seekingalpha.com and their article: “Verastem Tackles FDA Approval For Blood Cancer Drug” published on September 25, 2018 as well as Seekingalpha.com‘s news article titled: “Verastem Oncology prices registered direct offering of $150M convertible notes” with publication date: October 12, 2018.

Verastem, Inc. (NASDAQ:VSTM) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>